{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gandhi S"],"funding":["Bristol-Myers Squibb","Celgene","Regeneron","NCATS NIH HHS","Genentech","Takeda","Roswell Park Alliance Foundation","NIDDK NIH HHS","NIH/NCI","Boehringer Ingelheim","NCI NIH HHS","NIH"],"pagination":["e010058"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11575314"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(11)"],"pubmed_abstract":["Background
Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30-40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.Methods
Phase I study NCT04081389 e"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer."],"pmcid":["PMC11575314"],"funding_grant_id":["U24 CA224319","N/A","UL1 TR004419","CA224319","1P01CA234212","UL1 TR001412","CA263705","K08 CA279766","R03 TR004607","KL2 TR001413","2P30A016056-42","P01 CA234212","P30 CA196521","R33 CA263705","R03TR004607-01","1K08CA279766-01A1","CA196521","DK124165","UL1TR004419","U01 DK124165"],"pubmed_authors":["Attwood K","Miller J","Roudko V","Gnjatic S","Fitzpatrick V","De Souza I","Takabe K","O'Connor T","Kumar P","Wang J","Ozbey S","Cappuccino H","Levine EG","Ioannou G","Opyrchal M","Gandhi S","Kokolus KM","Cortes Gomez E","Slomba RT","Janes C","Young J","Kalinski P","Kalathil S","Edge S"],"additional_accession":[]},"is_claimable":false,"name":"Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer.","description":"Background
Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30-40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.Methods
Phase I study NCT04081389 e","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-15T09:42:02.117Z","creation":"2025-04-04T11:43:18.874Z"},"accession":"S-EPMC11575314","cross_references":{"pubmed":["39542655"],"doi":["10.1136/jitc-2024-010058"]}}